U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H18ClNO7.2Na
Molecular Weight 465.7927
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CL-316243

SMILES

C[C@]([H])(Cc1ccc2c(c1)OC(C(=O)[O-])(C(=O)[O-])O2)NC[C@@]([H])(c3cccc(c3)Cl)O.[Na+].[Na+]

InChI

InChIKey=FUZBPOHHSBDTJQ-CFOQQKEYSA-L
InChI=1S/C20H20ClNO7.2Na/c1-11(22-10-15(23)13-3-2-4-14(21)9-13)7-12-5-6-16-17(8-12)29-20(28-16,18(24)25)19(26)27;;/h2-6,8-9,11,15,22-23H,7,10H2,1H3,(H,24,25)(H,26,27);;/q;2*+1/p-2/t11-,15+;;/m1../s1

HIDE SMILES / InChI

Molecular Formula C20H18ClNO7
Molecular Weight 419.8131
Charge -2
Count
Stereochemistry EPIMERIC
Additional Stereochemistry No
Defined Stereocenters 2 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21170122 | https://www.ncbi.nlm.nih.gov/pubmed/11311069 | https://www.ncbi.nlm.nih.gov/pubmed/26988163

CL-316243 is a selective and highly specific β3-adrenoceptor agonist. CL 316243 possesses anti-obesity and anti-diabetic effects due to increasing brown adipose tissue thermogenesis and metabolic rate, and consequently may be useful for treating obesity as well as non-insulin-dependent diabetes mellitus in obese persons, without causing excessive side effects.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
220.0 nM [EC50]
262.0 µM [EC50]
111.0 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Beta3 adrenergic stimulation inhibits the opossum lower esophageal sphincter.
2002 Nov
Expression of glycerokinase in brown adipose tissue is stimulated by the sympathetic nervous system.
2003 Jun
The effects and selectivity of beta-adrenoceptor agonists in rat myometrium and urinary bladder.
2007 Nov 14
Patents

Patents

Sample Use Guides

The daily dose for rats was 1 mg/ kg body weight for 4 weeks
Route of Administration: Oral
Effect of CL (CL-316243) alone or in combination with ADA, PTX or WT on PI(3,4,5)P3 production were studied using rat epididymal adipocytes. [32P]orthophosphate-labeled adipocytes that were treated or not treated with ADA (2 U/ml, 10 min) or PTX (1 μg/ml, 60 min) were incubated for 1 min with or without CL (1 μM). In addition, [32P]orthophosphate-labeled adipocytes treated with or without WT (3 μM, 1 min) were incubated for 1 min with or without CL or INS (0.7 μM). Furthermore, adipocytes treated or not treated with ADA or PTX were incubated for 10 min with or without CL. The radioactivity of PI(3,4,5)P3 (PIP3) that were separated by TLC and the accumulation of cAMP in adipocytes were determined.
Substance Class Chemical
Created
by admin
on Sat Jun 26 13:11:03 UTC 2021
Edited
by admin
on Sat Jun 26 13:11:03 UTC 2021
Record UNII
CF9MRO9QWW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CL-316243
Common Name English
CL-316,243
Code English
HP-186
Code English
5-(2-((2-(3-CHLOROPHENYL)-2-HYDROXYETYL)AMINO)-PROPYL)-1,3-BENZODIOXOLE-2,2-DICARBOXYLIC ACID DISODIUM,(R-(R*,R*))
Common Name English
Code System Code Type Description
PUBCHEM
5312115
Created by admin on Sat Jun 26 13:11:03 UTC 2021 , Edited by admin on Sat Jun 26 13:11:03 UTC 2021
PRIMARY
FDA UNII
CF9MRO9QWW
Created by admin on Sat Jun 26 13:11:03 UTC 2021 , Edited by admin on Sat Jun 26 13:11:03 UTC 2021
PRIMARY
EPA CompTox
138908-40-4
Created by admin on Sat Jun 26 13:11:03 UTC 2021 , Edited by admin on Sat Jun 26 13:11:03 UTC 2021
PRIMARY
CAS
138908-40-4
Created by admin on Sat Jun 26 13:11:03 UTC 2021 , Edited by admin on Sat Jun 26 13:11:03 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> AGONIST
SHORT-ACTING
Related Record Type Details
ACTIVE MOIETY